Research progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Yisihare Julaiti ¹ ,  TianYanming ²

1. Graduate School of Xinjiang Medical University, Urumqi 830011, China;
2. Department of Ophthalmology, General Hospital of Xinjiang, Urumqi 830011, China;

Corresponding author：

TianYanming, Email: tianyanming@163.com

Keywords：

Diabetic retinopathy; Anti-vascular endothelial growth factor drugs; Dosage regimen; Pars plana vitrectomy; Review

DOI：

10.3760/cma.j.cn511434-20240708-00255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) has become an important cause of irreversible vision loss worldwide. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is an important adjunct to the treatment of DR. However, the current anti-VEGF treatment regimen is not uniform. Anti-vegf injection was preferred and then delayed combined with laser had better prognostic effect. The best time for operation was 5-7 days after injection of anti-VEGF. Pars plana vitrectomy (PPV), intraoperative and postoperative on-demand anti-VEGF injection can significantly improve patient prognosis and reduce complications, but further research is needed to strike a balance between the economic burden and the number of injections. Various anti-VEGF drugs have their own advantages for different diseases and should be selected according to the characteristics of the diseases and drugs. Anti-VEGF drugs combined with antioxidants may further improve DR Outcomes. Future studies should pay more attention to the optimization and personalization of anti-VEGF drug application programs to meet the therapeutic needs of different patients.

1.	Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2): 88-98. DOI: 10.1038/nrendo.2017.151.
2.	梁泽玉, 陈松, 何广辉, 等. 术前及术中2次应用康柏西普辅助玻璃体切割术治疗增生型糖尿病视网膜病变的临床研究[J]. 眼科新进展, 2019, 39(2): 162-167. DOI: 10.13389/j.cnki.rao.2019.0037.Liang ZY, Chen S, He GH, et al. Clinical observation of the application of conbercept preoperatively and intraoperatively assisted to the vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2019, 39(2): 162-167. DOI: 10.13389/j.cnki.rao.2019.0037.
3.	Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
4.	Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J/OL]. Front Endocrinol (Lausanne), 2024, 13: 1077669[2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36699020/. DOI: 10.3389/fendo.2022.1077669.
5.	Liu F, Xu Y, Ma Y. Taxifolin shows anticataractogenesis and attenuates diabetic retinopathy in STZ-diabetic rats via suppression of aldose reductase, oxidative stress, and MAPK signaling pathway[J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(4): 599-608. DOI: 10.2174/1871530319666191018122821.
6.	Julius A, Renuka RR, Hopper W, et al. Inhibition of aldose reductase by novel phytocompounds: a heuristic approach to treating diabetic retinopathy[J/OL]. Evid Based Complement Alternat Med, 2022, 2022: 9624118[2022-03-21]. https://pubmed.ncbi.nlm.nih.gov/35356240/. DOI: 10.1155/2022/9624118.
7.	刘家琦, 李凤鸣. 实用眼科学: 眼科学[M]. 人民卫生出版社, 2010. .Liu JQ, Li FM. Practical ophthalmology: Ophthalmology[M]. People's Medical Publishing House, 2010.
8.	Song A, Ghareeb A, Mehta A, et al. Infographic: intravitreous aflibercept vs vitrectomy with panretinal photocoagulation for vitreous haemorrhage from proliferative diabetic retinopathy[J]. Eye (Lond), 2022, 36(1): 8-9. DOI: 10.1038/s41433-021-01530-0.
9.	Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments[J/OL]. Int J Mol Sci, 2018, 19(6): 1816[2018-06-20]. https://pubmed.ncbi.nlm.nih.gov/29925789/. DOI: 10.3390/ijms19061816.
10.	Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy[J]. Ann Med, 2022, 54(1): 1089-1111. DOI: 10.1080/07853890.2022.2064541.
11.	Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review[J]. Int J Retina Vitreous, 2015, 1: 9. DOI: 10.1186/s40942-015-0010-y.
12.	Gonzalez-Cortes JH, Martinez-Pacheco VA, Gonzalez-Cantu JE, et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema[J]. Pharmaceutics, 2022, 15(1): 122. DOI: 10.3390/pharmaceutics15010122.
13.	李筱荣, 杨千惠. 美国眼科学会《糖尿病视网膜病变临床指南》解读[J]. 中华实验眼科杂志, 2020, 38(9): 795-798. DOI: 10.3760/cma.j.cn115989-20200518-00350.Li XR, Yang QH. The American Academy of Ophthalmology of diabetic retinopathy clinical guide interpretation[J]. Chin J Exp Ophthalmol, 2020, 38(9): 795-798. DOI: 10.3760/cma.j.cn115989-20200518-00350.
14.	Wang Z, Feng C, Yang R, et al. Large-area photoreceptor degeneration model in rabbits by photocoagulation and oxidative stress in the retina[J/OL]. Front Neurosci, 2021, 15: 617175[2021-06-10]. https://pubmed.ncbi.nlm.nih.gov/34177442/. DOI: 10.3389/fnins.2021.617175.
15.	Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic tetinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
16.	Reddy SV, Husain D. Panretinal photocoagulation: a review of complications[J]. Semin Ophthalmol, 2018, 33(1): 83-88. DOI: 10.1080/08820538.2017.1353820.
17.	Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods[J]. Surv Ophthalmol, 2023, 68(2): 147-174. DOI: 10.1016/j.survophthal.2022.11.008.
18.	李巧, 王凡, 杨宁, 等. 玻璃体腔注射康柏西普联合黄斑格栅光凝治疗视网膜中央静脉阻塞继发黄斑水肿的临床观察[J]. 中国眼耳鼻喉科杂志, 2021, 21(5): 341-344,349. DOI: 10.14166/j.issn.1671-2420.2021.05.006.Li Q, Wang F, Yang N, et al. Clinical observation of intravitreal injection of conbercept combined with macular grid photocoagulation in the treatment of macular edema secondary to central retinal vein occlusion[J]. Chin J Ophthalmol and Otorhinolaryngol, 2021, 21(5): 341-344,349. DOI: 10.14166/j.issn.1671-2420.2021.05.006.
19.	Yusuf IH, Henein C, Sivaprasad S. Infographic: panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR. net Protocol S[J/OL]. Eye (Lond), 2023, 2023: E1(2023-04-21)[2024-07-08]. https://pubmed.ncbi.nlm.nih.gov/37085719/. DOI: 10.1038/s41433-023-02396-0. [published online ahead of print].
20.	Fung THM, Abramson J, Ojha S, et al. Systemic effects of optos versus indirect ophthalmoscopy for retinopathy of prematurity screening[J]. Ophthalmology, 2018, 125(11): 1829-1832. DOI: 10.1016/j.ophtha.2018.06.001.
21.	Lubis PM, Prabaniswara MP, Victor AA. Comparison of micropulse subthreshold laser plus anti-vegf versus anti-vegf alone in diabetic macular edema: systematic review[J]. Indian J Ophthalmol, 2023, 71(11): 3448-3453. DOI: 10.4103/IJO.IJO_519_23.
22.	Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
23.	Goker YS, Ozdal PC, Erol YO, et al. Evaluation of radial peripapillary capillary density in patients with fuchs uveitis syndrome[J]. Graefe's Arch Clin Exp Ophthalmol, 2019, 257(12): 2735-2742. DOI: 10.1007/s00417-019-04491-z.
24.	Ciucci F, Ioele G, Bardocci A, et al. Central retinal thickness fluctuations in patients treated with anti-vegf for neovascular age related macular degeneration[J]. Eur J Ophthalmol, 2022, 32(4): 2388-2394. DOI: 10.1177/11206721211037820.
25.	马列, 黎晓新. 玻璃体腔注射雷珠单抗对增生性糖尿病视网膜病变玻璃体切割术后再出血的防治作用[J]. 中华实验眼科杂志, 2017, 35(1): 4. DOI: 10.3760/cma.j.issn.2095-0160.2017.01.014.Ma L, Li XX. Effect of intravitreal injection of ranibizumab on rebleeding after vitrectomy in patients with proliferative diabetic retinopathy[J]. Chin J Exp Ophthalmol, 2017, 35(1): 4. DOI: 10.3760/cma.j.issn.2095-0160.2017.01.014.
26.	Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings[J]. Ophthalmology, 2004, 111(6): 1215-1221. DOI: 10.1016/j.ophtha.2003.08.043.
27.	Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
28.	Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy[J]. Eye (Lond), 2009, 23(1): 108-111. DOI: 10.1038/sj.eye.6702983.
29.	徐玥. PDR围手术期玻璃体内抗VEGF药物注射的最佳时机初探[D]. 淮南: 安徽理工大学, 2021.Xu Y. A preliminary study on the optimal timing of intravitreal anti-VEGF drug injection during the perioperative period of PDR[D]. Huainan: Anhui University of Science and Technology, 2021.
30.	Castillo J, Aleman I, Rush SW, et al. Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation[J]. Am J Ophthalmol, 2017, 183: 1-10. DOI: 10.1016/j.ajo.2017.08.013.
31.	雷建平. 康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的疗效分析[J]. 上海医药, 2022, 43(13): 33-35,91. DOI: 10.3969/j.issn.1006-1533.2022.13.010.LEI JP. Efficacy analysis of conbercept assisted vitrectomy for proliferative diabetic retinopathy[J]. Shanghai Medicine, 2022, 43(13): 33-35,91. DOI: 10.3969/j.issn.1006-1533.2022.13.010.
32.	Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
33.	赵宇. 玻璃体切割术联合康柏西普治疗增殖性糖尿病视网膜病变的疗效研究[D]. 沈阳: 中国医科大学, 2022.Zhao Y. Efficacy of vitrectomy combined with conbercept in the treatment of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2022.
34.	刘进清. 康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的有效性及安全性[J]. 糖尿病新世界, 2022, 25(22): 167-170. DOI: 10.16658/j.cnki.1672-4062.2022.22.167.Liu JQ. Efficacy and safety of conbercept assisted vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Diabetes New World, 2022, 25(22): 167-170. DOI: 10.16658/j.cnki.1672-4062.2022.22.167.
35.	白旭旭. 增殖性糖尿病视网膜病变患者玻璃体切除术后不同抗VEGF治疗方案的疗效比较[D]. 延安: 延安大学, 2023.Bai XX. Comparison of the efficacy of different anti-VEGF treatment regimens in patients with proliferative diabetic retinopathy after vitrectomy[D]. Yan'an: Yan'an University, 2023.
36.	Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1102361[2023-01-23]. https://pubmed.ncbi.nlm.nih.gov/36755912/. DOI: 10.3389/fendo.2023.1102361.
37.	郑洪芳, 杨军红, 赵旭. 抗VEGF药物联合Ahmed青光眼引流阀治疗新生血管性青光眼的效果及安全性[J]. 临床医学, 2021, 41(5): 70-72. DOI: 10.19528/j.issn.1003-3548.2021.05.028.Zheng HF, Yang JH, Zhao X. Efficacy and safety of anti-VEGF drugs combined with Ahmed glaucoma valve in the treatment of neovascular glaucoma[J]. Clinical Medicine, 2021, 41(5): 70-72. DOI: 10.19528/j.issn.1003-3548.2021.05.028.
38.	Kalogeropoulos D, Moussa G, Sung VC, et al. Neovascular glaucoma: an update[J]. Klin Monbl Augenheilkd, 2023, 240(3): 305-315. DOI: 10.1055/a-1956-9348.
39.	Bai L, Tariq F, He YD, et al. Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade[J]. Int J Ophthalmol, 2021, 14(3): 456-460. DOI: 10.18240/ijo.2021.03.20.
40.	Sakamoto M, Hashimoto R, Yoshida I, et al. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy[J]. Clin Ophthalmol, 2018, 12: 2323-2329. DOI: 10.2147/OPTH.S184959.
41.	Liu WS, Li YJ. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a meta-analysis and systematic review[J]. Int J Ophthalmol, 2019, 12(9): 1479-1486. DOI: 10.18240/ijo.2019.09.17.
42.	Shirley M. Faricimab: first approval[J]. Drugs, 2022, 82(7): 825-830. DOI: 10.1007/s40265-022-01713-3.
43.	Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review[J/OL]. Int J Mol Sci, 2022, 23(16): 9424[2022-08-20]. https://pubmed.ncbi.nlm.nih.gov/36012690/. DOI: 10.3390/ijms23169424.
44.	Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: boulevard phase 2 randomized trial[J]. Ophthalmology, 2019, 126(8): 1155-1170. DOI: 10.1016/j.ophtha.2019.03.023.
45.	Wijesingha N, Gibson K, Willis JR, et al. Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from yosemite and rhine)[J/OL]. Eye (Lond), 2024, 2024: E1(2024-07-29)[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/39075261/. DOI: 10.1038/s41433-024-03249-0. [published online ahead of print].
46.	Wang M, Wang L, Gong Y, et al. Study on the effects of different anti-vegf drugs on fibrovascular membranes of proliferative diabetic retinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103530[2023-04-14]. https://pubmed.ncbi.nlm.nih.gov/37060987/. DOI: 10.1016/j.pdpdt.2023.103530.
47.	Krick TW, Bressler NM. Recent clinically relevant highlights from the diabetic retinopathy clinical research network[J]. Curr Opin Ophthalmol, 2018, 29(3): 199-205. DOI: 10.1097/ICU.0000000000000472.
48.	Stewart MW. The clinical utility of aflibercept for diabetic macular edema[J]. Diabetes Metab Syndr Obes, 2015, 8: 473-482. DOI: 10.2147/DMSO.S72792.
49.	臧涵怡, 包欣, 赵伟. 雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究[J]. 眼科新进展, 2021, 41(11): 1072-1076. DOI: 10.13389/j.cnki.rao.2021.0225.Zang HY, Bao X, Zhao W. Comparison of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration[J]. Rec Adv Ophthalmol, 2021, 41(11): 1072-1076. DOI: 10.13389/j.cnki.rao.2021.0225.
50.	张祺, 段淯平, 马培茹, 等. 阿柏西普T&E方案与雷珠单抗3+prn方案治疗初发DME的回顾性对照研究[J]. 中国医院药学杂志, 2021, 41(21): 2213-2216. DOI: 10.13286/j.1001-5213.2021.21.11.Zhang Q, Duan YP, Ma PR, et al. A retrospective comparative study of aflibercept T&E regimen and ranibizumab 3+prn regimen in the treatment of newly diagnosed DME[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(21): 2213-2216. DOI: 10.13286/j.1001-5213.2021.21.11.
51.	汪彬, 屈晓勇, 欧阳君. 康柏西普1+PRN和3+PRN方案治疗湿性年龄相关性黄斑变性的效果比较[J]. 中国医学创新, 2022, 19(26): 60-64. DOI: 10.3969/j.issn.1674-4985.2022.26.014.Wang B, Qu XY, Ouyang YJ. Comparison of the efficacy of conbercept 1+PRN and 3+PRN regimens in the treatment of wet age-related macular degeneration[J]. Medical Innovation of China, 2022, 19(26): 60-64. DOI: 10.3969/j.issn.1674-4985.2022.26.014.
52.	Li S, Tao Y, Yang M, et al. Aflibercept 5+prn with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+prn with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1286736[2024-02-22]. https://pubmed.ncbi.nlm.nih.gov/38455651/. DOI: 10.3389/fendo.2024.1286736.
53.	林翠婷, 卢庆梅, 胡秋明. 探讨两种PRN治疗方案下康柏西普治疗糖尿病视网膜病变的临床疗效[J]. 糖尿病新世界, 2023, 26(17): 27-30. DOI: 10.16658/j.cnki.1672-4062.2023.17.027.Lin CT, Lu QM, Hu QM. To investigate the clinical efficacy of conbercept in the treatment of diabetic retinopathy under two PRN treatment regimens[J]. Diabetes New World, 2023, 26(17): 27-30. DOI: 10.16658/j.cnki.1672-4062.2023.17.027.
54.	Gao J, Tao L, Jiang Z. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies[J/OL]. Redox Rep, 2023, 28(1): 2272386[2023-12-02]. https://pubmed.ncbi.nlm.nih.gov/38041593/. DOI: 10.1080/13510002.2023.2272386.
55.	Melero R, Quiroz-Rodríguez ME, Lara-Hernández F, et al. Corrigendum to "genetic interaction in the association between oxidative stress and diabetes in the spanish population"[J]. Free Radic Biol Med, 2023, 207: 181-182. DOI: 10.1016/j.freeradbiomed. 2023.07.017.
56.	Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
57.	Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond[J]. Diabetologia, 2018, 61(1): 29-38. DOI: 10.1007/s00125-017-4435-8.
58.	Fan X, Xu M, Ren Q, et al. Downregulation of fatty acid binding protein 4 alleviates lipid peroxidation and oxidative stress in diabetic retinopathy by regulating peroxisome proliferator-activated receptor γ-mediated ferroptosis[J]. Bioengineered, 2022, 13(4): 10540-10551. DOI: 10.1080/21655979.2022.2062533.
59.	Lee CH, Lui DT, Cheung CY, et al. Circulating AFABP, FGF21, and PEDF levels as prognostic biomarkers of sight-threatening diabetic retinopathy[J/OL]. J Clin Endocrinol Metab, 2023, 108(9): e799-e806[2023-08-18]. https://pubmed.ncbi.nlm.nih.gov/36856742/. DOI: 10.1210/clinem/dgad112.
60.	Yozgat Z, Doğan M, Sabaner MC, et al. Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema[J]. Int Ophthalmol, 2021, 41(5): 1783-1798. DOI: 10.1007/s10792-021-01737-w.

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2): 88-98. DOI: 10.1038/nrendo.2017.151.
2. 梁泽玉, 陈松, 何广辉, 等. 术前及术中2次应用康柏西普辅助玻璃体切割术治疗增生型糖尿病视网膜病变的临床研究[J]. 眼科新进展, 2019, 39(2): 162-167. DOI: 10.13389/j.cnki.rao.2019.0037.Liang ZY, Chen S, He GH, et al. Clinical observation of the application of conbercept preoperatively and intraoperatively assisted to the vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Rec Adv Ophthalmol, 2019, 39(2): 162-167. DOI: 10.13389/j.cnki.rao.2019.0037.
3. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
4. Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J/OL]. Front Endocrinol (Lausanne), 2024, 13: 1077669[2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36699020/. DOI: 10.3389/fendo.2022.1077669.
5. Liu F, Xu Y, Ma Y. Taxifolin shows anticataractogenesis and attenuates diabetic retinopathy in STZ-diabetic rats via suppression of aldose reductase, oxidative stress, and MAPK signaling pathway[J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(4): 599-608. DOI: 10.2174/1871530319666191018122821.
6. Julius A, Renuka RR, Hopper W, et al. Inhibition of aldose reductase by novel phytocompounds: a heuristic approach to treating diabetic retinopathy[J/OL]. Evid Based Complement Alternat Med, 2022, 2022: 9624118[2022-03-21]. https://pubmed.ncbi.nlm.nih.gov/35356240/. DOI: 10.1155/2022/9624118.
7. 刘家琦, 李凤鸣. 实用眼科学: 眼科学[M]. 人民卫生出版社, 2010. .Liu JQ, Li FM. Practical ophthalmology: Ophthalmology[M]. People's Medical Publishing House, 2010.
8. Song A, Ghareeb A, Mehta A, et al. Infographic: intravitreous aflibercept vs vitrectomy with panretinal photocoagulation for vitreous haemorrhage from proliferative diabetic retinopathy[J]. Eye (Lond), 2022, 36(1): 8-9. DOI: 10.1038/s41433-021-01530-0.
9. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments[J/OL]. Int J Mol Sci, 2018, 19(6): 1816[2018-06-20]. https://pubmed.ncbi.nlm.nih.gov/29925789/. DOI: 10.3390/ijms19061816.
10. Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy[J]. Ann Med, 2022, 54(1): 1089-1111. DOI: 10.1080/07853890.2022.2064541.
11. Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review[J]. Int J Retina Vitreous, 2015, 1: 9. DOI: 10.1186/s40942-015-0010-y.
12. Gonzalez-Cortes JH, Martinez-Pacheco VA, Gonzalez-Cantu JE, et al. Current treatments and innovations in diabetic retinopathy and diabetic macular edema[J]. Pharmaceutics, 2022, 15(1): 122. DOI: 10.3390/pharmaceutics15010122.
13. 李筱荣, 杨千惠. 美国眼科学会《糖尿病视网膜病变临床指南》解读[J]. 中华实验眼科杂志, 2020, 38(9): 795-798. DOI: 10.3760/cma.j.cn115989-20200518-00350.Li XR, Yang QH. The American Academy of Ophthalmology of diabetic retinopathy clinical guide interpretation[J]. Chin J Exp Ophthalmol, 2020, 38(9): 795-798. DOI: 10.3760/cma.j.cn115989-20200518-00350.
14. Wang Z, Feng C, Yang R, et al. Large-area photoreceptor degeneration model in rabbits by photocoagulation and oxidative stress in the retina[J/OL]. Front Neurosci, 2021, 15: 617175[2021-06-10]. https://pubmed.ncbi.nlm.nih.gov/34177442/. DOI: 10.3389/fnins.2021.617175.
15. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic tetinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
16. Reddy SV, Husain D. Panretinal photocoagulation: a review of complications[J]. Semin Ophthalmol, 2018, 33(1): 83-88. DOI: 10.1080/08820538.2017.1353820.
17. Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods[J]. Surv Ophthalmol, 2023, 68(2): 147-174. DOI: 10.1016/j.survophthal.2022.11.008.
18. 李巧, 王凡, 杨宁, 等. 玻璃体腔注射康柏西普联合黄斑格栅光凝治疗视网膜中央静脉阻塞继发黄斑水肿的临床观察[J]. 中国眼耳鼻喉科杂志, 2021, 21(5): 341-344,349. DOI: 10.14166/j.issn.1671-2420.2021.05.006.Li Q, Wang F, Yang N, et al. Clinical observation of intravitreal injection of conbercept combined with macular grid photocoagulation in the treatment of macular edema secondary to central retinal vein occlusion[J]. Chin J Ophthalmol and Otorhinolaryngol, 2021, 21(5): 341-344,349. DOI: 10.14166/j.issn.1671-2420.2021.05.006.
19. Yusuf IH, Henein C, Sivaprasad S. Infographic: panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR. net Protocol S[J/OL]. Eye (Lond), 2023, 2023: E1(2023-04-21)[2024-07-08]. https://pubmed.ncbi.nlm.nih.gov/37085719/. DOI: 10.1038/s41433-023-02396-0. [published online ahead of print].
20. Fung THM, Abramson J, Ojha S, et al. Systemic effects of optos versus indirect ophthalmoscopy for retinopathy of prematurity screening[J]. Ophthalmology, 2018, 125(11): 1829-1832. DOI: 10.1016/j.ophtha.2018.06.001.
21. Lubis PM, Prabaniswara MP, Victor AA. Comparison of micropulse subthreshold laser plus anti-vegf versus anti-vegf alone in diabetic macular edema: systematic review[J]. Indian J Ophthalmol, 2023, 71(11): 3448-3453. DOI: 10.4103/IJO.IJO_519_23.
22. Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
23. Goker YS, Ozdal PC, Erol YO, et al. Evaluation of radial peripapillary capillary density in patients with fuchs uveitis syndrome[J]. Graefe's Arch Clin Exp Ophthalmol, 2019, 257(12): 2735-2742. DOI: 10.1007/s00417-019-04491-z.
24. Ciucci F, Ioele G, Bardocci A, et al. Central retinal thickness fluctuations in patients treated with anti-vegf for neovascular age related macular degeneration[J]. Eur J Ophthalmol, 2022, 32(4): 2388-2394. DOI: 10.1177/11206721211037820.
25. 马列, 黎晓新. 玻璃体腔注射雷珠单抗对增生性糖尿病视网膜病变玻璃体切割术后再出血的防治作用[J]. 中华实验眼科杂志, 2017, 35(1): 4. DOI: 10.3760/cma.j.issn.2095-0160.2017.01.014.Ma L, Li XX. Effect of intravitreal injection of ranibizumab on rebleeding after vitrectomy in patients with proliferative diabetic retinopathy[J]. Chin J Exp Ophthalmol, 2017, 35(1): 4. DOI: 10.3760/cma.j.issn.2095-0160.2017.01.014.
26. Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings[J]. Ophthalmology, 2004, 111(6): 1215-1221. DOI: 10.1016/j.ophtha.2003.08.043.
27. Modarres M, Nazari H, Falavarjani KG, et al. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy[J]. Eur J Ophthalmol, 2009, 19(5): 848-852. DOI: 10.1177/112067210901900526.
28. Ishikawa K, Honda S, Tsukahara Y, et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy[J]. Eye (Lond), 2009, 23(1): 108-111. DOI: 10.1038/sj.eye.6702983.
29. 徐玥. PDR围手术期玻璃体内抗VEGF药物注射的最佳时机初探[D]. 淮南: 安徽理工大学, 2021.Xu Y. A preliminary study on the optimal timing of intravitreal anti-VEGF drug injection during the perioperative period of PDR[D]. Huainan: Anhui University of Science and Technology, 2021.
30. Castillo J, Aleman I, Rush SW, et al. Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation[J]. Am J Ophthalmol, 2017, 183: 1-10. DOI: 10.1016/j.ajo.2017.08.013.
31. 雷建平. 康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的疗效分析[J]. 上海医药, 2022, 43(13): 33-35,91. DOI: 10.3969/j.issn.1006-1533.2022.13.010.LEI JP. Efficacy analysis of conbercept assisted vitrectomy for proliferative diabetic retinopathy[J]. Shanghai Medicine, 2022, 43(13): 33-35,91. DOI: 10.3969/j.issn.1006-1533.2022.13.010.
32. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
33. 赵宇. 玻璃体切割术联合康柏西普治疗增殖性糖尿病视网膜病变的疗效研究[D]. 沈阳: 中国医科大学, 2022.Zhao Y. Efficacy of vitrectomy combined with conbercept in the treatment of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2022.
34. 刘进清. 康柏西普辅助玻璃体切割治疗增生型糖尿病视网膜病变的有效性及安全性[J]. 糖尿病新世界, 2022, 25(22): 167-170. DOI: 10.16658/j.cnki.1672-4062.2022.22.167.Liu JQ. Efficacy and safety of conbercept assisted vitrectomy in the treatment of proliferative diabetic retinopathy[J]. Diabetes New World, 2022, 25(22): 167-170. DOI: 10.16658/j.cnki.1672-4062.2022.22.167.
35. 白旭旭. 增殖性糖尿病视网膜病变患者玻璃体切除术后不同抗VEGF治疗方案的疗效比较[D]. 延安: 延安大学, 2023.Bai XX. Comparison of the efficacy of different anti-VEGF treatment regimens in patients with proliferative diabetic retinopathy after vitrectomy[D]. Yan'an: Yan'an University, 2023.
36. Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1102361[2023-01-23]. https://pubmed.ncbi.nlm.nih.gov/36755912/. DOI: 10.3389/fendo.2023.1102361.
37. 郑洪芳, 杨军红, 赵旭. 抗VEGF药物联合Ahmed青光眼引流阀治疗新生血管性青光眼的效果及安全性[J]. 临床医学, 2021, 41(5): 70-72. DOI: 10.19528/j.issn.1003-3548.2021.05.028.Zheng HF, Yang JH, Zhao X. Efficacy and safety of anti-VEGF drugs combined with Ahmed glaucoma valve in the treatment of neovascular glaucoma[J]. Clinical Medicine, 2021, 41(5): 70-72. DOI: 10.19528/j.issn.1003-3548.2021.05.028.
38. Kalogeropoulos D, Moussa G, Sung VC, et al. Neovascular glaucoma: an update[J]. Klin Monbl Augenheilkd, 2023, 240(3): 305-315. DOI: 10.1055/a-1956-9348.
39. Bai L, Tariq F, He YD, et al. Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade[J]. Int J Ophthalmol, 2021, 14(3): 456-460. DOI: 10.18240/ijo.2021.03.20.
40. Sakamoto M, Hashimoto R, Yoshida I, et al. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy[J]. Clin Ophthalmol, 2018, 12: 2323-2329. DOI: 10.2147/OPTH.S184959.
41. Liu WS, Li YJ. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a meta-analysis and systematic review[J]. Int J Ophthalmol, 2019, 12(9): 1479-1486. DOI: 10.18240/ijo.2019.09.17.
42. Shirley M. Faricimab: first approval[J]. Drugs, 2022, 82(7): 825-830. DOI: 10.1007/s40265-022-01713-3.
43. Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review[J/OL]. Int J Mol Sci, 2022, 23(16): 9424[2022-08-20]. https://pubmed.ncbi.nlm.nih.gov/36012690/. DOI: 10.3390/ijms23169424.
44. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: boulevard phase 2 randomized trial[J]. Ophthalmology, 2019, 126(8): 1155-1170. DOI: 10.1016/j.ophtha.2019.03.023.
45. Wijesingha N, Gibson K, Willis JR, et al. Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from yosemite and rhine)[J/OL]. Eye (Lond), 2024, 2024: E1(2024-07-29)[2021-07-08]. https://pubmed.ncbi.nlm.nih.gov/39075261/. DOI: 10.1038/s41433-024-03249-0. [published online ahead of print].
46. Wang M, Wang L, Gong Y, et al. Study on the effects of different anti-vegf drugs on fibrovascular membranes of proliferative diabetic retinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103530[2023-04-14]. https://pubmed.ncbi.nlm.nih.gov/37060987/. DOI: 10.1016/j.pdpdt.2023.103530.
47. Krick TW, Bressler NM. Recent clinically relevant highlights from the diabetic retinopathy clinical research network[J]. Curr Opin Ophthalmol, 2018, 29(3): 199-205. DOI: 10.1097/ICU.0000000000000472.
48. Stewart MW. The clinical utility of aflibercept for diabetic macular edema[J]. Diabetes Metab Syndr Obes, 2015, 8: 473-482. DOI: 10.2147/DMSO.S72792.
49. 臧涵怡, 包欣, 赵伟. 雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究[J]. 眼科新进展, 2021, 41(11): 1072-1076. DOI: 10.13389/j.cnki.rao.2021.0225.Zang HY, Bao X, Zhao W. Comparison of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration[J]. Rec Adv Ophthalmol, 2021, 41(11): 1072-1076. DOI: 10.13389/j.cnki.rao.2021.0225.
50. 张祺, 段淯平, 马培茹, 等. 阿柏西普T&E方案与雷珠单抗3+prn方案治疗初发DME的回顾性对照研究[J]. 中国医院药学杂志, 2021, 41(21): 2213-2216. DOI: 10.13286/j.1001-5213.2021.21.11.Zhang Q, Duan YP, Ma PR, et al. A retrospective comparative study of aflibercept T&E regimen and ranibizumab 3+prn regimen in the treatment of newly diagnosed DME[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(21): 2213-2216. DOI: 10.13286/j.1001-5213.2021.21.11.
51. 汪彬, 屈晓勇, 欧阳君. 康柏西普1+PRN和3+PRN方案治疗湿性年龄相关性黄斑变性的效果比较[J]. 中国医学创新, 2022, 19(26): 60-64. DOI: 10.3969/j.issn.1674-4985.2022.26.014.Wang B, Qu XY, Ouyang YJ. Comparison of the efficacy of conbercept 1+PRN and 3+PRN regimens in the treatment of wet age-related macular degeneration[J]. Medical Innovation of China, 2022, 19(26): 60-64. DOI: 10.3969/j.issn.1674-4985.2022.26.014.
52. Li S, Tao Y, Yang M, et al. Aflibercept 5+prn with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+prn with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1286736[2024-02-22]. https://pubmed.ncbi.nlm.nih.gov/38455651/. DOI: 10.3389/fendo.2024.1286736.
53. 林翠婷, 卢庆梅, 胡秋明. 探讨两种PRN治疗方案下康柏西普治疗糖尿病视网膜病变的临床疗效[J]. 糖尿病新世界, 2023, 26(17): 27-30. DOI: 10.16658/j.cnki.1672-4062.2023.17.027.Lin CT, Lu QM, Hu QM. To investigate the clinical efficacy of conbercept in the treatment of diabetic retinopathy under two PRN treatment regimens[J]. Diabetes New World, 2023, 26(17): 27-30. DOI: 10.16658/j.cnki.1672-4062.2023.17.027.
54. Gao J, Tao L, Jiang Z. Alleviate oxidative stress in diabetic retinopathy: antioxidant therapeutic strategies[J/OL]. Redox Rep, 2023, 28(1): 2272386[2023-12-02]. https://pubmed.ncbi.nlm.nih.gov/38041593/. DOI: 10.1080/13510002.2023.2272386.
55. Melero R, Quiroz-Rodríguez ME, Lara-Hernández F, et al. Corrigendum to "genetic interaction in the association between oxidative stress and diabetes in the spanish population"[J]. Free Radic Biol Med, 2023, 207: 181-182. DOI: 10.1016/j.freeradbiomed. 2023.07.017.
56. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
57. Hammes HP. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond[J]. Diabetologia, 2018, 61(1): 29-38. DOI: 10.1007/s00125-017-4435-8.
58. Fan X, Xu M, Ren Q, et al. Downregulation of fatty acid binding protein 4 alleviates lipid peroxidation and oxidative stress in diabetic retinopathy by regulating peroxisome proliferator-activated receptor γ-mediated ferroptosis[J]. Bioengineered, 2022, 13(4): 10540-10551. DOI: 10.1080/21655979.2022.2062533.
59. Lee CH, Lui DT, Cheung CY, et al. Circulating AFABP, FGF21, and PEDF levels as prognostic biomarkers of sight-threatening diabetic retinopathy[J/OL]. J Clin Endocrinol Metab, 2023, 108(9): e799-e806[2023-08-18]. https://pubmed.ncbi.nlm.nih.gov/36856742/. DOI: 10.1210/clinem/dgad112.
60. Yozgat Z, Doğan M, Sabaner MC, et al. Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema[J]. Int Ophthalmol, 2021, 41(5): 1783-1798. DOI: 10.1007/s10792-021-01737-w.

Chinese Journal of Ocular Fundus Diseases

Latest ArticlesResearch progress on the effects of different dosing regimens of anti-vascular endothelial growth factor drugs on diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Format

Content